Company news

DiaSorin S.p.A. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

DiaSorin S p A Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay

May 19, 2026

DiaSorin S p A Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President

May 4, 2026

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024

March 20, 2026

DiaSorin S p A signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform

March 19, 2026

DiaSorin S p A introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN

February 24, 2026

DiaSorin S p A submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver

February 3, 2026

DiaSorin S p A has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL

January 29, 2026

DiaSorin S p A signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel

January 26, 2026

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer.

January 22, 2026

DiaSorin S p A receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform

December 30, 2025

DiaSorin S p A receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIASON NES Molecular Diagnostics platform

December 28, 2025

DiaSorin S p A submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance

November 24, 2025

DiaSorin: , in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark

November 18, 2025

DiaSorin S p A receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration

October 31, 2025

DiaSorin S p A signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX

October 22, 2025

DiaSorin S p A launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark

September 19, 2025

Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed

July 31, 2025

DiaSorin S p A submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver

July 2, 2025

DiaSorin S p A announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®

June 7, 2025

DiaSorin S p A receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX®

April 18, 2025

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999

April 3, 2025

DiaSorin S p A launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark

March 18, 2025

Decks

The 5 newest of 115 decks. Every deck is listed under its year.